A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer

Shuo ChenDepartment of Thoracic Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, People’s Republic of China, [email protected]

Bin HuDepartment of Thoracic Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, People’s Republic of China, [email protected]

Hui LiDepartment of Thoracic Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, People’s Republic of China, [email protected]Correspondence[email protected]

Pages 7691-7697 | Published online: 31 Oct 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

TravisWDPathology of lung cancerClin Chest Med201132466969222054879
PubMed Web of Science ®Google Scholar
SpiroSGRuddRMSouhamiRLChemotherapy versus supportive care in advanced non-small-cell lung cancer: improved survival without detriment to quality of lifeThorax2004591082883615454647
PubMed Web of Science ®Google Scholar
NSCLC Meta-Analyses Collaborative GroupChemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trialsJ Clin Oncol200826284617462518678835
PubMed Web of Science ®Google Scholar
ChangSDaiMRenJSChenYHGuoLWEstimates and prediction on incidence, mortality and prevalence of lung cancer in China in 2008Zhonghua Liu Xing Bing Xue Za Zhi201233439139422781412
PubMedGoogle Scholar
WoodDENational Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Lung Cancer ScreeningThorac Surg Clin201525218519725901562
PubMed Web of Science ®Google Scholar
SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
PubMed Web of Science ®Google Scholar
ReckMKaiserRMellemgaardADocetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialLancet Oncol201415214315524411639
PubMed Web of Science ®Google Scholar
GettingerSNHornLGandhiLOverall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerJ Clin Oncol201533182004201225897158
PubMed Web of Science ®Google Scholar
LarkinJLaoCDUrbaWJEfficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical TrialsJAMA Oncol20151443344026181250
PubMed Web of Science ®Google Scholar
PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
PubMed Web of Science ®Google Scholar
SchadendorfDHodiFSRobertCPooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaJ Clin Oncol201533171889189425667295
PubMed Web of Science ®Google Scholar
TopalianSLSznolMMcdermottDFSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabJ Clin Oncol201432101020103024590637
PubMed Web of Science ®Google Scholar
PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet200937396741525153119410716
PubMed Web of Science ®Google Scholar
BorghaeiHPaz-AresLHornLNivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerN Engl J Med2015373171627163926412456
PubMed Web of Science ®Google Scholar
BrahmerJReckampKLBaasPNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerN Engl J Med2015373212313526028407
PubMed Web of Science ®Google Scholar
CarboneDPReckMPaz-AresLFirst-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung CancerN Engl J Med2017376252415242628636851
PubMed Web of Science ®Google Scholar
HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysisStat Med200221111539155812111919
PubMed Web of Science ®Google Scholar
HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
PubMed Web of Science ®Google Scholar
DominguesDTurnerASilvaMDImmunotherapy and lung cancer: current developments and novel targeted therapiesImmunotherapy20146111221123525496336
PubMed Web of Science ®Google Scholar
KatsuyaYHorinouchiHAsaoTExpression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapyLung Cancer20169941027565906
PubMed Web of Science ®Google Scholar
Cancer Genome Atlas Research NetworkComprehensive genomic characterization of squamous cell lung cancersNature2012489741751952522960745
PubMed Web of Science ®Google Scholar
Cancer Genome Atlas Research NetworkComprehensive molecular profiling of lung adenocarcinomaNature2014511751154355025079552
PubMed Web of Science ®Google Scholar
AngYLTanHLSooRABest practice in the treatment of advanced squamous cell lung cancerTher Adv Respir Dis20159522423525902866
PubMed Web of Science ®Google Scholar
TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
PubMed Web of Science ®Google Scholar
TaubeJMKleinABrahmerJRAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyClin Cancer Res201420195064507424714771
PubMed Web of Science ®Google Scholar
HornLSpigelDRVokesEENivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)J Clin Oncol201735353924393329023213
PubMed Web of Science ®Google Scholar
TaubeJMAndersRAYoungGDColocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escapeSci Transl Med20124127127ra137
Google Scholar
HerbstRSSoriaJCKowanetzMPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature2014515752856356725428504
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date